Stanford University
Showing 531-540 of 2,562 Results
-
Carlos Centeno Lairet
Affiliate, Ethics In Society
BioCarlos is a 2026 Ethics & Tech Practitioner Fellow at the McCoy Family Center for Ethics in Society. He co-founded SOMOS Civic Lab. At the lab, the team is researching and designing tools to democratize generative AI in Global Majority countries. Somos is part of the UNDP AI Trust & Safety Programme, and it's supported by the Pulitzer Center's AI Accountability program. As MIT Emerging Talent Director, he equips learners from migrant and refugee communities with computer science skills. He co-founded and directed MIT's Governance Innovation Initiative, as Associate Director of Innovation; co-designed and launched MIT's first Governance Innovation Research Fellowship, and hosted MIT's "Power to the Who" governance innovation podcast. He was previously at the UN for 10 years, where he worked in community and government preparedness to natural disasters based in Latin America, Asia and Africa. His AI (NLP) prototype ALIA was a Google launchpad finalist in Munich (2018). He has supported investigative journalism projects at Pro Publica on disappearances and detentions by the US federal government.
-
Sierra Mei Lin Centkowski, MD
Clinical Assistant Professor, Dermatology
BioDr. Sierra Mei Lin Centkowski is a board-certified Clinical Assistant Professor of Dermatology at Stanford University. She received both her medical degree and Master’s in Bioethics from the Perelman School of Medicine at the University of Pennsylvania and completed her dermatology residency at Stanford. Her clinical interests include general dermatology, including skin cancer, acne, psoriasis, atopic dermatitis and dermatologic surgery. She believes that patient empowerment and partnership provide the foundation for effective, compassionate and holistic care.
-
Alma-Martina Cepika
Assistant Professor of Surgery (General Surgery)
Current Research and Scholarly InterestsCepika Lab studies human immune tolerance. Using cellular immunology, genomics, and gene engineering, we aim to understand: 1) the role of human thymic regulatory T cells (Tregs) and inducible type 1 regulatory T (Tr1) cells in resistance to anti-tumor immunity and cancer immunotherapy, and 2) the interplay between innate and adaptive immunity in the pathogenesis of human inflammatory bowel disease (IBD). Our overarching goal is to leverage our discoveries for improving patient outcomes.
